Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
ISSN: 1537-4513
Titre abrégé: J Immunother
Pays: United States
ID NLM: 9706083
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
17
01
2024
accepted:
08
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.
Identifiants
pubmed: 38545827
doi: 10.1097/CJI.0000000000000513
pii: 00002371-990000000-00094
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74:134–148.
Takahashi H, Tada Y, Saotome T, et al. Phase II Trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125–134.
Hamza A, Roberts D, Su S, et al. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagnos Pathol. 2019;40:49–52.
Sato F, Akiba J, Kawahara A, et al. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. J Oral Pathol. 2018;47:683–690.
Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–137.
Shin JW, Kim S, Ha S, et al. The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab. Biomolecules. 2019;9:629.
Scherl C, Haderlein M, Agaimy A, et al. Outcome and management of rare high-grade “salivary” adenocarcinoma: The important role of adjuvant (chemo)radiotherapy. Strahlenther Onkol. 2019;195:1050–1059.
Niwa K, Kawakita D, Nagao T, et al. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep. 2020;10:16988.
Sato R, Kumai T, Ishida Y, et al. The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study. Laryngoscope Investig Otolaryngol. 2022;7:1808–1813.
Sato T, Maeta T, Abe R, et al. Successful treatment with nivolumab in a patient with metastatic salivary duct carcinoma. Case Rep Oncol. 2021;14:343–346.